NEUROHORMONAL MODULATION FOR THE PREVENTION OF ANTHRACYCLINE-INDUCED CARDIAC DYSFUNCTION IN PATIENTS WITH BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

Clicks: 8
ID: 331169
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #326 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Anthracycline-induced cardiac dysfunction (AICD) is cardiac injury associated with potentially cardiotoxic anthracycline therapy, and remains a significant complication for breast cancer patients. Neurohormonal modulation, a therapeutic strategy used primarily in heart failure, including renin–angiotensin system inhibitors and beta-blockers, has been proposed to prevent AICD. Several trials have reported potential cardioprotective benefits, but effectiveness remains uncertain. Therefore, we aimed to evaluate the effect of neurohormonal modulation on AICD incidence and left ventricular ejection fraction (LVEF) in patients receiving anthracycline. Methods A comprehensive literature search was conducted to identify randomised controlled trials (RCTs) investigating the cardioprotective effect of neurohormonal modulation therapy in patients administered with anthracyclines. The primary outcome was AICD incidence, and the secondary outcome was change in LVEF from baseline to the end of study. The meta-analysis was conducted using RevMan with a random-effects model. Results Fourteen RCTs involving 1,821 patients were included. Neurohormonal modulation was associated with significant reduction in the incidence of AICD (risk ratio [RR] 0.45, 95% confidence interval [CI] 0.31–0.67; p<0.0001; I²=60%). Subgroup analyses demonstrated consistent benefit with renin–angiotensin system inhibitors (RR 0.39, 95% CI 0.22–0.69) and beta-blockers (RR 0.53, 95% CI: 0.28–0.99). Neurohormonal modulation therapy also demonstrated preservation of LVEF (mean difference [MD] 2.09%, 95% CI 1.44–2.74; p<0.00001; I²=87%). Conclusion Neurohormonal modulation significantly reduces the incidence of AICD and preserves LVEF in breast cancer patients receiving anthracycline-based chemotherapy, supporting its role as a cardioprotective strategy.Figure 1.Forest plots of neurohormonal modulation on (A) incidence of anthracycline-induced cardiac dysfunction and (B) change in left ventricular ejection fraction
Reference Key
openalex_W7220409857 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors R B Sidabukke, N P Simangunsong, L A A Hadid
Are you one of these authors? Claim your profile
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.040
URL
https://doi.org/10.1093/eurheartjsupp/suag119.040
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.